Drug Profile
IONIS PTP1BRx
Alternative Names: Antisense PTP-1B gene therapy; IONIS-PTP1BRx; ISIS-404173; ISIS-PTP1BRxLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antihyperglycaemics; Antisense oligonucleotides; Insulin sensitisers
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in USA (Parenteral)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 03 Feb 2015 Isis Pharmaceuticals releases efficacy and adverse event data from a phase II trial in Type 2 diabetes mellitus